TBIO.jpg
Translate Bio Appoints Richard Wooster as Chief Scientific Officer
April 08, 2019 07:30 ET | Translate Bio, Inc.
LEXINGTON, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
TBIO.jpg
Translate Bio Appoints Pasquale (Pat) Sacco as Senior Vice President of Technical Operations
April 01, 2019 07:30 ET | Translate Bio, Inc.
-- New role expands Company’s manufacturing expertise to support pipeline of mRNA therapeutics in development for rare, genetic diseases -- LEXINGTON, Mass., April 01, 2019 (GLOBE NEWSWIRE) --...
TBIO.jpg
Translate Bio Granted U.S. Patent Relating to Messenger RNA (mRNA) Delivery
March 26, 2019 07:30 ET | Translate Bio, Inc.
LEXINGTON, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
TBIO.jpg
Translate Bio Announces Fourth Quarter and Full Year 2018 Financial Results and Reviews Recent Highlights
March 21, 2019 16:29 ET | Translate Bio, Inc.
LEXINGTON, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
CureVac Logo mit Claim RGB.jpg
CureVac Announces Late-Breaking Poster Presentation at American Association of Cancer Research (AACR) Annual Meeting 2019
March 21, 2019 07:00 ET | CureVac AG
TÜBINGEN, Germany and BOSTON, March 21, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced it will present...
TBIO.jpg
Translate Bio Announces Publication of Preclinical Data Demonstrating Efficacy of Systemic mRNA Delivery in Fabry Disease Model in the Journal Molecular Therapy
March 18, 2019 07:30 ET | Translate Bio, Inc.
LEXINGTON, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
CureVac Logo mit Claim RGB.jpg
CEPI awards US$ 34M contract to CureVac to advance The RNA Printer™—a disruptive, transportable mRNA vaccine manufacturing platform that can rapidly combat multiple diseases
February 27, 2019 07:30 ET | CureVac AG
OSLO, Norway, Feb. 27, 2019 (GLOBE NEWSWIRE) -- The Coalition for Epidemic Preparedness Innovations (CEPI) and CureVac AG, a biopharmaceutical company pioneering the field of mRNA-based vaccines,...
CureVac Logo mit Claim RGB.jpg
CureVac to Present at the 8th Annual Leerink Partners Global Healthcare Conference
February 19, 2019 07:00 ET | CureVac AG
TÜBINGEN, Germany and BOSTON, Feb. 19, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Dan...
TBIO.jpg
Translate Bio to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference
February 14, 2019 07:30 ET | Translate Bio, Inc.
LEXINGTON, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
CureVac Logo mit Claim RGB.jpg
CureVac Appoints Stefan Mueller, Ph.D., as Vice President Preclinical
February 04, 2019 07:00 ET | CureVac AG
TÜBINGEN, Germany and BOSTON, Feb. 04, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced today the...